



Drugs prescribed by year GLP1 100 75 50 Subtype cana % total new drug prescriptions 25 dapa dulaglutide empa 0 exenatide SGLT2 liraglutide 100 lixisenatide Therapy 75 -GLP1 - SGLT2 50 25 0 2015 2016 2017 2008 2009 2012 2013 2014 2018 2019 2007 2010 2011

Predicted HbA1c change, baseline adjusted



Predicted HbA1c change by drugline, baseline adjusted 2 2 GLP1 SGLT2 0 -10-20 3 3 GLP1 SGLT2 Subtype 0 cana Predicted Response (mmol/mol) -10 dapa dulaglutide -20 empa exenatide 4 4 liraglutide GLP1 SGLT2 lixisenatide 0 -10 Therapy -20 GLP1 - SGLT2 5 5 GLP1 SGLT2 0 -10-20 2010 2015 2010 2015 yrdrugstart

Initial HbA1c by subtype, per year



Drugs previously prescribed by Therapy subtype

